Exact Sciences Corporation (EXAS) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EXAS Revenue Growth
Revenue Breakdown (FY 2025)
EXAS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EXAS Revenue Analysis (2014–2025)
As of May 8, 2026, Exact Sciences Corporation (EXAS) generated trailing twelve-month (TTM) revenue of $3.25 billion, reflecting exceptional growth of +23.1% year-over-year. The most recent quarter (Q4 2025) recorded $878.4 million in revenue, up 3.2% sequentially.
Looking at the longer-term picture, EXAS's 5-year compound annual growth rate (CAGR) stands at +16.8%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $3.25 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows EXAS's business is primarily driven by Screening (78%), and Precision Oncology (22%). With over half of revenue concentrated in Screening, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including GH (+39.6% YoY), NTRA (+35.9% YoY), and ILMN (+1.2% YoY), EXAS has underperformed the peer group in terms of revenue growth. Compare EXAS vs GH →
EXAS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EXASCurrent | $3.2B | +23.1% | +16.8% | -6.4% | |
 GH | $982M | +39.6% | +27.9% | -44.4% | |
 NTRA | $2.3B | +35.9% | +42.6% | -13.4% | |
 ILMN | $4.3B | +1.2% | +6.0% | 19.9% | |
 LH | $14.0B | +7.3% | -0.0% | 10.9% | |
 DGX | $11.0B | +11.0% | +3.2% | 14.5% |
EXAS Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.25B | +17.7% | $2.26B | 69.7% | $-206,298,000 | -6.4% |
| 2024 | $2.76B | +10.4% | $1.92B | 69.5% | $-1,048,703,000 | -38.0% |
| 2023 | $2.50B | +19.9% | $1.76B | 70.5% | $-215,012,000 | -8.6% |
| 2022 | $2.08B | +17.9% | $1.42B | 68.3% | $-593,511,000 | -28.5% |
| 2021 | $1.77B | +18.5% | $1.31B | 74.0% | $-855,678,000 | -48.4% |
| 2020 | $1.49B | +70.2% | $1.14B | 76.2% | $-767,696,000 | -51.5% |
| 2019 | $876.3M | +92.8% | $659.6M | 75.3% | $-233,782,000 | -26.7% |
| 2018 | $454.5M | +70.9% | $336.5M | 74.0% | $-159,471,000 | -35.1% |
| 2017 | $266.0M | +167.7% | $186.8M | 70.2% | $-118,310,000 | -44.5% |
| 2016 | $99.4M | +152.0% | $54.2M | 54.5% | $-169,016,000 | -170.1% |
Full EXAS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See EXAS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EXAS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EXAS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEXAS — Frequently Asked Questions
Quick answers to the most common questions about buying EXAS stock.
Is EXAS's revenue growth accelerating or slowing?
EXAS revenue is accelerating at +23.1% year-over-year, exceeding the 5-year CAGR of +16.8%. TTM revenue reached $3.2B. Growth momentum has increased versus prior periods.
What is EXAS's long-term revenue growth rate?
Exact Sciences Corporation's 5-year revenue CAGR of +16.8% reflects the sustained expansion pattern. Current YoY growth of +23.1% is above this long-term average.
How is EXAS's revenue distributed by segment?
EXAS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.